Sales have most likely been boosted in the Innovative Medicines division on the back of Entresto, Pluvicto, Kesimpta, Scemblix and Kisqali’s continued strong performance in the third quarter.
Hence, Sandoz division and selected portions of corporate activities attributable to Sandoz’s business, as well as certain expenses related to the distribution, will be reported as discontinued operations. However, earlier in the month, Novartis completed the spin-off of its generic and biosimilar unit, Sandoz, following which Sandoz became an independent company. Novartis operated under two segments - Innovative Medicines and Sandoz (generics). Let's see how things are shaping up for this announcement. Novartis AG price-consensus-eps-surprise-chart | Novartis AG Quote Novartis AG Price, Consensus and EPS Surprise
